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Abstract
Objective
Vancomycin-resistant Enterococcus (VRE) is today one of the principal
microorganisms implicated in nosocomial infections. Thus, a study was carried out
with the objective of evaluating its epidemiology at a tertiary-level teaching hospital.
Methods
This was a three-year retrospective epidemiological study conducted from 2000 to
2002. Samples of VRE-positive clinical cultures at a 660-bed university hospital were
analyzed. The incidence of VRE and the main anatomical sites and hospital units from
which it was isolated were defined. Differences between the variables over the three
years of the study were verified, and these were considered significant when p<0.05.
Results
There was a progressive increase in the vancomycin resistance in the clinical cultures
that were positive for Enterococcus spp., over the three years of the study. In 2000,
9.5% of the samples were vancomycin-resistant, and this increased to 14.7% in 2001
and 15.8% in 2002. The hospital units with the largest numbers of isolates were,
respectively, the emergency ward (19.5%) and the general intensive care unit (15%).
The anatomical sites with the highest amounts of isolates included: urine (36%) and
blood (20%).
Conclusions
With the progressive increase in the incidence of vancomycin resistance and the VRE
rate, it is concluded that more effective control measures are needed for deterring the
dissemination of VRE.
INTRODUCTION
Vancomycin-resistant Enterococcus (VRE) is one
of the principal pathogens that cause hospital infec-
tions. Today, its presence in urinary infections, surgi-
cal site infections and bacteremia is notable.10 Ente-
rococcus spp. is a normal inhabitant of the gastroin-
testinal tract, and 16 species have been described.
Two species are predominant: E. faecalis and E.
faecium. The Enterococcus genus presents intrinsic
resistance to various antimicrobial agents and also
progressive acquired resistance to antimicrobial
agents that are commonly utilized for treating
enterococcal infections (e.g. ampicillin and
aminoglycosides).8 Vancomycin resistance is much
more recent21 and basically occurs through the pro-
duction of peptidoglycan precursors in the cell wall
that weakly bond to vancomycin, thereby impeding
its action of blocking cell wall synthesis.12 Since it
was first isolated in Brazil in 1996,7 vancomycin-
resistant Enterococcus has become a frequent con-
cern among hospital epidemiologists because of its
potential for dissemination through contact. This has
led to the implementation of measures for avoiding
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it is common to use ampicillin alone or in associa-
tion with gentamycin or streptomycin.
The objective of the present study was to assess the
incidence distribution within hospitals of clinical cul-
tures positive for vancomycin-resistant Enterococcus,
and also the principal sites from which it is isolated.
METHODS
This was a retrospective epidemiological study based
on the evaluation of clinical cultures positive for VRE.
It was carried out in a 660-bed university teaching
hospital between January 2000 and December 2002.
The samples were seeded in specific culturing me-
dia, after identification as Enterococcus spp. by
means of bile-esculin. The disk diffusion test using
Mueller-Hinton (MH) agar was performed to con-
firm the vancomycin resistance using a conventional
method.16 The Enterococcus species in the sample
were not identified.
Statistical analysis using the chi-squared test was
performed to verify the significance of the variables
over the three years of the study. Differences were
considered significant when p<0.05.
The present study was approved by the research
ethics committee of Escola Paulista de Medicina,
Federal University of São Paulo (Unifesp).
RESULTS
Over the study period, 240 cultures positive for VRE
were observed, of which 44 were in 2000, 88 in 2001
and 108 in 2002. Thus, there was a 100% increase in
2001 in relation to 2000 and 22% increase in 2002 in
relation to 2001. Table 1 shows the principal sites
from which VRE was isolated each year, and the
number of cultures per site. The progressive increase
in isolation from urine samples was statistically sig-
nificant (p<0.0001). The reduction in its incidence
in isolates from surgical wounds over the three years
of the study was also significant (p<0.0001).
its dissemination within the hospital environment.
These measures basically consist of barrier precau-
tions and guidance on the use of antimicrobial agents,
with the particular aim of reducing the use of vanco-
mycin, cephalosporins and antianaerobic antibiotics
such as carbapenems, metronidazole and clindamycin.
Winston et al,23 in a study on the epidemiology of
VRE, found that among 181 patients with positive
cultures for VRE, a large majority came from urine
cultures (69%), and the species was E. faecium in
100% of the cases. Rosenberg et al19 described the
increase in the incidence of VRE in clinical samples
in several hospitals in São Francisco, California, be-
tween 1994 and 1998. There are no reports of studies
in Brazil that have observed the epidemiology of
clinical cultures that are positive for VRE; hence the
importance of the present study. Sader et al20 recently
published an analysis of a microbiological surveil-
lance study in Brazil that showed a rate of vancomy-
cin resistance of around 7% in 2001.
Vancomycin-resistant Enterococcus was first iso-
lated in a surveillance culture from a patient with
acute lymphocytic leukemia, in 1998.6 Subse-
quently, it started to be frequently isolated in clini-
cal cultures, with rapid dissemination through sev-
eral sectors of the hospital. In view of this, a surveil-
lance program was begun in two intensive care units
(general ICU and pneumonology ICU), in which the
patients with colonization were diagnosed by means
of collecting rectal swabs. This program had the
objective of isolating these patients from contact
and minimizing the risk of transmission to other
patients.
The Enterococcus spp. isolated in Brazilian hospi-
tals is basically E. faecalis, which still has a good
sensitivity profile in relation to ampicillin, differing
from the American model in which there are signifi-
cant and growing quantities of E. faecium with a much
wider resistance profile.13 There are already reports of
resistance to recently launched antimicrobial agents
with activity against Enterococcus spp, such as
linezolid and quinupristin-dalfopristin.8,11 In Brazil,
VRE: vancomycin-resistant Enterococcus
NS: Not significant
Table 1 - Numbers of isolates positive for vancomycin-resistant Enterococcus, according to year of the study and site.
Site/Year 2000 2001 2002 p
(No. of cultures) (44) (88) (108)
Blood culture 11 (25%) 18 (20%) 21 (19%) NS
Urine culture 8 (18%) 35 (40%) 45 (42%) P<0.0001
Surgical wound 7 (16%) 7 (8%) 5 (4%) P<0.0001
Central catheter 4 (9%) 9 (10%) 6 (5%) NS
Scar 4 (9%) 5 (6%) 2 (2%) NS
Others 10 (23%) 14 (16%) 29 (27%) NS
Total 44 88 108
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In 2000, VRE was isolated from 17 units of the
hospital, while in 2001 it was isolated from 26 units,
thus characterizing an increase of 52%. In 2002, it
was isolated from 25 units. Table 2 shows the units
from which VRE was isolated, and also the numbers
of cultures from each unit.
In 2000, the incidence of vancomycin resistance in
clinical cultures was 9.5%, increasing to 14.7% in
2001 and to 15.8% in 2002.
The unit that presented the greatest numbers of cul-
tures positive for VRE was the emergency ward, with
47 cultures (19.5%), followed by the general intensive
care unit, with 36 cultures (15%) and by nephrology
with 15 cultures (6.2%). There were statistically sig-
nificant differences in the numbers of isolates in the
emergency ward (p<0.0001), pneumonology intensive
care unit (p<0.0001) and vascular surgery (p<0.0001)
over the period studied.
The percentages of VRE in cultures positive for
Enterococcus spp were 9.5% in 2000, 14.7% in 2001
and 15.8% in 2002. The numbers of VRE per 1000
patients-day were, respectively, 0.21 in 2000, 0.46 in
2001 and 0.6 in 2002. The numbers of VRE per 1000
clinical cultures were, respectively, 3.1 in 2000, 5.9
in 2001 and 7.3 in 2002.
DISCUSSION
Vancomycin-resistant Enterococcus today is one
of the principal pathogens causing hospital infec-
tions. It presents wide dissemination in large-sized
hospitals, and notably in those with teaching activi-
ties, like the one where the present study was made.
Between 1989 and 1997 in the United States, there
was an increase from 0.4% to 23.2% among intensive
care unit patients, and from 0.3% to 15.4% in other
units.4 Colonization or infection by VRE has been
associated with a variety of factors, including the
length of hospitalization, underlying disease (par-
ticularly renal insufficiency and neutropenia) and
liver transplantation.1 Patients colonized by VRE
carry the organism in their intestinal flora and may
remain colonized for prolonged periods (up to two
years).10 Vancomycin resistance has been classified
into five phenotypes: VanA to VanE. Of these, only
the phenotype VanC is intrinsically present, in two
species (E. gallinarum and E. casseliflavus): all the
others are acquired in the two principal species (E.
faecalis and E. faecium).10 After introduction into a
given hospital, Enterococcus presents a great capac-
ity for dissemination, affecting various sectors and
creating an endemicity profile that makes subsequent
eradication attempts very difficult.15 Lai et al12 re-
ported that, with the utilization of all the recom-
mended interventions, it was possible to reduce the
numbers of VRE cases, but not to eradicate them.
However, there was better control over the use of van-
comycin and an increase in the expenses on gloves
and gowns.
In the university hospital of the present study, the
data present a progressive increase in the incidence
of VRE over the three years, to reach a level of 15.8%
of the strains of Enterococcus spp. presenting vanco-
mycin resistance in 2002. This indicates a worrying
situation, given that the SENTRY surveillance study,
which included Brazilian data, showed a VRE rate of
only 2% for Latin America.18
The present study also describes a progressive in-
crease in the numbers of cultures positive for VRE, in
relation to the numbers of patients hospitalized over
the period of the study (patients-day). There was a
year-by-year increase in the number of cultures posi-
tive for VRE despite the reduction in the number of
patients-day per year of the study. There was also a
year-by-year increase in the number of cultures posi-
tive for VRE, in relation to the average number of
cultures per year performed at the central laboratory
(data presented per 1,000 cultures/year), which was
3.1/1,000 cultures/year in 2000 and rose to 7.3/1,000
cultures/year in 2002.
Cereda et al,5 studying 250 strains from the same
hospital as in the present study that were isolated in
Table 2 - Numbers of cultures positive for vancomycin-resistant Enterococcus, according to years of the study and hospital
.Unit/Year 2000 2001 2002 p
( No. of cultures) (44) (88) (108)
Emergency ward 8 (18%) 10 (11%) 29 (27%) P<0.0001
General ICU 6 (14%) 14 (16%) 16 (15%) NS
Pneumology ICU 8 (18%) 3 (3%) 3 (3%) P<0.0001
Vascular surgery 4 (9%) 2 (2%) 0 (0%) P<0.0001
Nephrology 4 (9%) 8 (9%) 3 (3%) NS
Neurosurgery 1 (2%) 5 (6%) 6 (5%) NS
Pediatrics 1 (2%) 4 (5%) 7 (6%) NS
Others 12 (27%) 42 (48%) 44 (41%) P<0.0001
Total 44 88 108
ICU: intensive care unit
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1994 and 1995, did not find any vancomycin resist-
ance. However eight isolates (3.2%) with intermedi-
ate sensitivity were found, thus already presaging
the subsequent development of resistance, which
was first found in 1998, in a surveillance culture
performed on a patient with acute lymphoid leuk-
emia who was submitted to a bone marrow trans-
plant.6 After this initial isolation of VRE, weekly
surveillance culturing was instituted in 2000, in the
two intensive care units where the greatest numbers
of cases had arisen up to that time (general ICU and
pneumonology ICU). Weekly culturing was per-
formed on the gastrointestinal tract, by means of
rectal swabs taken from the patients who had stayed
for more than five days in the two intensive care
units. If the cultures were positive for VRE, the pa-
tients were isolated until their discharge.
The present report also confirms that there is greater
incidence of VRE in critical care units. It was seen
that the emergency ward, which functions as a semi-
intensive care unit, was the unit that presented the
greatest incidence of cases during the study period,
along with the general intensive care unit. Urine
(36.6%) and the bloodstream (20.8%) were the two
sites most involved in positivity for VRE, followed
by surgical wounds (7.9%) and catheter tips (7.9%),
as described in the literature.10
The pneumonology intensive care unit presented a
progressive reduction in incidence. This was one of
the intensive care units where surveillance was being
done by means of collecting rectal swabs and where
patients with cultures positive for VRE were being
isolated. On the other hand, in the general intensive
care unit, where surveillance swabs were also being
taken, a progressive increase in cases over the three
years of the study was observed. Units with progres-
sive increases in cases need to be carefully watched,
and the collection of surveillance cultures from pa-
tients close to the index case is indicated, in order to
attempt to avoid further dissemination of the VRE,
especially in outbreak situations.
After VRE appeared in the hospital of the present
study, measures based on the recommendations from
the Centers for Disease Control (CDC), Atlanta,
United States, were implemented. In these recom-
mendations, the rational use of vancomycin, surveil-
lance of units at risk, with isolation of patients who
have become infected and colonized, and the im-
portant role of the laboratory in identifying resist-
ance, are emphasized.3 Byers et al,2 starting from an
outbreak of VRE, showed that by implementing the
measures recommended by the CDC, they were able
to reduce the dissemination of the pathogen through
the hospital. They also found that proximity to a
non-isolated case was an important risk factor for
VRE acquisition, as was a history of trauma or use
of metronidazole.
Surveillance measures are extremely important for
containing VRE. Studies have shown that the inci-
dence of colonized patients in a given hospital is ten
times greater than the number of infected patients.
This contributes towards very rapid transmission to
other patients, because if patients are not identified
using surveillance methods, it is impossible to im-
plement contact barriers.14
Over the last few years, there has been a concern
that Enterococcus might transmit vancomycin resist-
ance to Staphylococcus aureus, which is a much more
prevalent and pathogenic organism. Such transmis-
sion has been achieved in vitro,17 and it became real-
ity in 2002, with the isolation of vancomycin-resist-
ant S. aureus in two patients who also presented VRE
of VanA phenotype.21,22
Because of the large numbers of VRE cases, sur-
veillance measures need to be implemented in the
emergency ward, with the aim of reducing the inci-
dence of VRE and also its dissemination to other units
in the hospital. It must be borne in mind that this unit
functions as the gateway for patients going to other
sectors of the hospital.
In summary, vancomycin-resistant Enterococcus is
a pathogen with progressive incidence in our envi-
ronment, as has already occurred in other countries.
It is important to identify and control it, particularly
by means of barrier precautions and appropriate use
of antimicrobial agents. Surveillance cultures are an
important resource, in association with the above
measures, for attempting to avoid greater dissemina-
tion of VRE in units at risk, such as intensive care
units, transplantation and hemodialysis units and
immunodepressed patient units.
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